Inovio shares fall 25% after $75 million offering at $1.05

By Daniel Okafor

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) shares fell 25% on Friday after the company priced a $75 million public offering at $1.05 per share, according to Kala Ghazi’s TradingView report. The deal gave the clinical-stage biotechnology company more cash while expanding its share count and exposing existing holders to dilution.

What did Inovio price?

Ghazi reported that the public offering would generate approximately $75 million in gross proceeds. That total comes before underwriting discounts, commissions and offering expenses. It also excludes any money from an underwriter’s option to buy additional shares.

The base financing therefore does not equal the cash Inovio can spend after the transaction closes. Final proceeds depend on whether the underwriter exercises the additional allotment and on the usual fees and costs attached to the sale. In short, $75 million is the gross amount; the cash retained after deductions will be less.

Ghazi said Inovio develops and commercializes DNA medicines designed to treat and protect people from HPV-related diseases, cancer and infectious diseases. The source said a public offering can supply needed money for research, development and commercialization. That is the operating case for raising equity rather than waiting for another financing source.

Who is running the sale?

Jefferies and Piper Sandler serve as joint book-running managers for the offering. H.C. Wainwright & Co. serves as lead manager. Ghazi said their roles include managing the sale and distribution of the newly issued shares.

The report described the participation of the three firms as typical for a public equity offering of this type. Their named roles distinguish a joint book-running arrangement from H.C. Wainwright’s lead-manager position.

Why did the shares fall 25%?

Ghazi attributed the immediate decline to the offering’s size and pricing, together with the dilution investors face when a company issues new shares. He also noted that biotechnology valuations and sentiment can react sharply to financing announcements, particularly when newly sold shares carry a price below recent trading levels.

That mechanism matters because more capital can accelerate development work, but a larger share base reduces each existing investor’s proportional claim on future value. The report framed the one-day reaction as a judgment on the near-term cost of funding rather than a final verdict on Inovio’s longer-term plans.

What does the November 10 report change?

Inovio previously announced that it would release third-quarter 2026 financial results after the market close on November 10, 2026. Ghazi said investors were likely to focus on cash position, spending and pipeline progress. They would also look for management commentary on how the new capital fits into the company’s broader strategy.

The offering makes those disclosures more consequential. Cash and spending figures will help investors judge how much capital the financing provides and how quickly the money moves into the business. Pipeline updates will show whether management can convert that spending into development progress. Neither the size of the raise nor the share-price reaction answers those questions on its own.

What should investors measure next?

Ghazi identified three linked tests: how much capital Inovio ultimately raises, how quickly it uses that capital and whether upcoming financial and clinical updates support the company’s longer-term plans. The first test is mechanical. The latter two depend on operating evidence rather than the offering announcement.

At $1.05 per share, more shares now divide the same company among more owners. The November 10 release is the next scheduled checkpoint identified in the report, and its cash, spending and pipeline details will show whether added capital offsets the dilution.